Apuli Maricel's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Feb 18, 2026
- Accession no.
- 0001470831-26-000186
- Filed
- Feb 18, 2026
- Trade date
- Feb 16-17, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $37.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Apuli MaricelCIK 0002058197 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2026 | Common Stock | FTax withholdingDisposed | −4,349 | $75.25 | −$327,262.25 | 124,455 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −510 | $74.31 | −$37,898.1 | 123,945 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.